13F reference period
Q2 2026
Security Snapshot
Yarrow Bioscience, Inc. - common stock, par value $0.0001 (VYNE) Institutional Ownership
CUSIP: 92941V308
13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026
Institutions Reporting
43
Shares (Excl. Options)
14.46M
Full value: 14,463,252 · shares · 30 Jun 2026Price
$0.65
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / common stock, par value $0.0001
- Symbol
- VYNE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 14,463,252
- Total 13F value
- $9,410,643
- Portfolio coverage rank
- 0%
- Share change
- +305,204
- Value change
- +$205,369
- Number of holders
- 43
- Shares outstanding
- 33,403,382
- SEC-reported price per share
- $0.51
- Insider filing price
- $0.51
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- VYNE - Yarrow Bioscience, Inc. - common stock, par value $0.0001 is tracked under CUSIP 92941V308.
- 43 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 43 to 43 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$8.46M
Full value: $8,458,542 · USD · 31 Mar 2026.$9.41M
Full value: $9,410,643 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 43 institutions filings for Q2 2026.
Security key
92941V308
13F reference period
Q2 2026
13F holders
43
13D/G owners
3
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92941V308:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
VYNE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Zhang Xiaofan | 14% | +137% | $2,888,491 | +$1,710,879 | 4,595,118 | +145% | Zhang Xiaofan | 13 Jul 2026 |
| Nantahala Capital Management, LLC | 6% | $1,195,000 | 2,000,000 | Nantahala Capital Management, LLC | 31 Mar 2026 | |||
| CITADEL ADVISORS LLC | 0% | -103% | $1,250 | -$367,360 | 3,732 | -100% | Kenneth Griffin | 30 Sep 2025 |
As of 30 Jun 2026,
43
institutional investors reported holding
shares of
Yarrow Bioscience, Inc. - common stock, par value $0.0001 (VYNE).
This represents
43%
of the company’s total
outstanding shares.
14.46M
Full value: 14,463,252 · shares · 30 Jun 202633.4M
Full value: 33,403,382 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
43%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 8.8% | 2,950,000 | +177% | 0.09% | $1,919,565 |
| Nantahala Capital Management, LLC | 6% | 2,000,000 | 0% | 0.08% | $1,301,400 |
| Lynx1 Capital Management LP | 4.9% | 1,628,700 | 0% | 0.12% | $1,059,795 |
| Shay Capital LLC | 4.4% | 1,456,651 | -9.5% | 0.1% | $947,843 |
| Deeter Investments LLP | 3% | 1,000,000 | 0% | 0.1% | $650,700 |
| T3 Companies, LLC | 2.8% | 945,000 | 0% | 0.7% | $614,912 |
| BRAIDWELL LP | 2.7% | 916,077 | 0% | 0.02% | $596,091 |
| KVP Capital Advisors, LP | 1.5% | 500,551 | 0% | 0.24% | $325,709 |
| CITADEL ADVISORS LLC | 1.4% | 468,457 | -8.9% | 0% | $304,825 |
| TWO SIGMA INVESTMENTS, LP | 1.3% | 438,818 | +2.9% | 0% | $285,539 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 381,797 | 0% | 0% | $248,000 |
| Ikarian Capital, LLC | 0.79% | 264,912 | 0% | 0.03% | $172,379 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.79% | 264,557 | 0% | 0% | $172,227 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.77% | 258,203 | -20% | 0% | $168,017 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 183,443 | 0% | 0% | $119,421 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.36% | 118,957 | +106% | 0% | $77,405 |
| Rangeley Capital, LLC | 0.34% | 113,064 | -4.2% | 0.07% | $73,571 |
| XTX Topco Ltd | 0.24% | 78,721 | -50% | 0% | $51,224 |
| GSA CAPITAL PARTNERS LLP | 0.21% | 71,533 | 0% | $47,000 | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.18% | 61,269 | 0.03% | $39,868 | |
| UBS Group AG | 0.18% | 58,597 | -67% | 0% | $38,147 |
| BlackRock, Inc. | 0.13% | 44,404 | 0% | 0% | $28,894 |
| NORTHERN TRUST CORP | 0.13% | 43,677 | +89% | 0% | $28,421 |
| JANE STREET GROUP, LLC | 0.12% | 40,974 | -57% | 0% | $26,662 |
| TWO SIGMA SECURITIES, LLC | 0.12% | 40,697 | 0% | $26,482 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Headline period
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 0 | $0 | -$637,596 | $0.51 | 0 |
| 2026 Q2 | 14,463,252 | $9,410,643 | +$205,369 | $0.65 | 43 |
| 2026 Q1 | 14,158,548 | $8,458,542 | +$2,898,813 | $0.60 | 43 |
| 2025 Q4 | 8,179,397 | $4,743,526 | +$1,869,192 | $0.58 | 39 |
| 2025 Q3 | 3,924,005 | $1,315,944 | -$9,032,746 | $0.34 | 31 |
| 2025 Q2 | 8,048,768 | $13,279,291 | +$1,503,898 | $1.65 | 44 |
| 2025 Q1 | 7,109,939 | $11,401,092 | -$2,382,241 | $1.58 | 36 |
| 2024 Q4 | 7,028,274 | $23,320,995 | +$606,162 | $3.35 | 34 |
| 2024 Q3 | 7,312,555 | $14,256,902 | -$1,226,342 | $1.88 | 31 |
| 2024 Q2 | 7,942,286 | $16,030,293 | +$243,077 | $1.97 | 30 |
| 2024 Q1 | 6,405,086 | $19,663,149 | +$378,435 | $3.07 | 29 |
| 2023 Q4 | 7,863,834 | $18,322,345 | +$17,207,859 | $2.33 | 32 |
| 2023 Q3 | 360,099 | $1,445,870 | -$33,734 | $4.04 | 20 |
| 2023 Q2 | 375,960 | $1,532,386 | +$198,131 | $4.10 | 19 |
| 2023 Q1 | 335,259 | $1,031,948 | +$1,031,948 | $3.08 | 19 |